Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B
Department of Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
J Pediatr Hematol Oncol. 1995 Nov;17(4):342-5. doi: 10.1097/00043426-199511000-00011.
Central venous access devices (CVAD) have been used with increasing frequency in recent years among pediatric patients. We retrospectively reviewed our experience in 25 children and young adults with sickle cell disease (SCD) over a 4 1/2 year period in an attempt to define occurrence rates of perioperative complications, thrombosis requiring catheter removal, and infectious episodes.
The setting was a university-associated tertiary children's hospital. Patients were 25 children and young adults (ages 8 months to 23 years) with SCD who required CVAD placement between February 1987 and April 1992. A total of 31 catheters (totally implantable ports and partially implanted catheters) were placed for 17,444 patient catheter days.
Rates of significant perioperative complications, thrombotic events requiring catheter removal, and infectious episodes were recorded. No perioperative complications were noted. Five episodes of catheter occlusion requiring replacement occurred in two patients (0.29 per 1,000 catheter patient days, involving 8% of patients and 16% of catheters). Fifteen episodes of catheter-associated bacteremia occurred in eight patients (0.86 per 1,000 catheter patient days involving 32% of patients and 26% of catheters). Three catheters required removal because of infection unresponsive to antibiotic therapy.
The occurrence of thrombosis requiring catheter removal and infection in our population of patients with SCD was comparable to that reported in patients with malignant disease, cystic fibrosis and acquired immune deficiency syndrome. CVAD represents an effective, reliable, and reasonably safe means of establishing and maintaining venous access for a selective group of children and young adults with SCD who have limited peripheral venous access and require intravenous therapies.
近年来,中心静脉通路装置(CVAD)在儿科患者中的使用频率越来越高。我们回顾性分析了25例镰状细胞病(SCD)儿童和青年患者在4年半时间内的治疗经验,以确定围手术期并发症、因血栓形成而需拔除导管以及感染事件的发生率。
研究地点为一所与大学相关的三级儿童医院。患者为25例年龄在8个月至23岁之间的SCD儿童和青年,他们在1987年2月至1992年4月期间需要置入CVAD。共置入31根导管(完全植入式端口和部分植入式导管),累计使用17444个患者导管日。
记录了严重围手术期并发症、因血栓形成而需拔除导管以及感染事件的发生率。未发现围手术期并发症。两名患者发生了5次导管阻塞需要更换(每1000个导管患者日0.29次,涉及8%的患者和16%的导管)。8名患者发生了15次导管相关菌血症(每1000个导管患者日0.86次,涉及32%的患者和26%的导管)。三根导管因抗生素治疗无效的感染而需要拔除。
我们的SCD患者群体中因血栓形成而需拔除导管和感染的发生率与恶性疾病、囊性纤维化和获得性免疫缺陷综合征患者的报告发生率相当。对于外周静脉通路有限且需要静脉治疗的特定SCD儿童和青年群体,CVAD是建立和维持静脉通路的一种有效、可靠且相对安全的方法。